Beta blockade during and after myocardial infarction: An overview of the randomized trials

Progress in Cardiovascular Diseases

Volumn 27, Issue 5, 1985, Pages 335-371

  Yusuf, Salim ^a   Peto, Richard ^a   Lewis, John ^a   Collins, Rory ^a   Sleight, Peter ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPRENOLOL; ATENOLOL; ATROPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; LABETALOL; METOPROLOL; OXPRENOLOL; PINDOLOL; PRACTOLOL; PRENALTEROL; PROPRANOLOL; SOTALOL; TIMOLOL;

ADVERSE DRUG REACTION; BETA ADRENERGIC RECEPTOR BLOCKING; BRONCHOSPASM; COLD LIMB; DEPRESSION; DRUG THERAPY; FATALITY; FATIGUE; HALLUCINATION; HEART; HEART ARRHYTHMIA; HEART INFARCTION; HEART INFARCTION SIZE; HUMAN; IMPOTENCE; INSOMNIA; INTOXICATION; LONG TERM CARE; LUNG TOXICITY; MALE GENITAL SYSTEM; NERVOUS SYSTEM; NEUROTOXICITY; PREVENTION; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; REPRODUCTIVE TOXICITY; RESPIRATORY SYSTEM; REVIEW; SUDDEN DEATH; THERAPY;

ADRENERGIC BETA-ANTAGONISTS; ARRHYTHMIA; CLINICAL TRIALS; CORONARY DISEASE; HUMAN; LONG-TERM CARE; METHODS; MYOCARDIAL INFARCTION; RANDOM ALLOCATION;

EID: 0021909115     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0033-0620(85)80003-7     Document Type: Article

References (157)

1. Clinical experience with beta-adrenergic blocking agents in myocardial ischameia: a dilemma and a challenge
2. Natural history of acute coronary heart attacks: A community study
3. Incidence and presentation of myocardial infarction in an English community
4. Coronary heart attacks in East London
5. Estimation of infarct size in man and its relation to prognosis
6. Relation of cardiac complications to SGOT level in acute myocardial infarction
7. Enzymatic indices of myocardial necrosis: Influence of short-and longterm prognosis after myocardial infarction
8. Myocardial changes associated with cardiogenic shock
9. Infarct size estimated from serial serum creatine phosphokinase in relation to left ventricular hemodynamics
10. Treatment of acute myocardial infarction with propranolol: Further studies on enzyme appearance and subsequent left ventricular function in treated and control patients with developing infarcts
11. Factors influencing infarct size following experimental coronary occlusions
12. Effects of coronary perfusion during myocardial hypoxia: Comparison of metabolic and hemodynamic events with global ischemia and hypoxemia
13. Effect of hypoxemia on the extent of myocardial necrosis after experimental coronary occlusion
14. Effect of acute anemia on experimental myocardial ischemia
15. The effect of hypoglycemia on myocardial ischemic injury during acute experimental coronary artery occlusion
16. Plasma catecholamines and carbohydrate metabolism in patients with acute myocardial infarction
17. Effect of reducing circulating free fatty acids on ventricular arrhythmias during myocardial infarction and on ST-segment depression during exercise-induced ischemia
18. Effect of free fatty acids on myocardial function and oxygen consumption in intact dogs
19. Propranolol in the treatment of acute myocardial infarction; effect on myocardial oxygenation and hemodynamics
20. Effect of free fatty acids on myocardial function and metabolism in the ischemic dog heart
21. Isoproterenol-induced “coronary steal”: Metabolic observations in human coronary heart disease
22. Effect of isoproterenol on collateral blood flow in ischemic myocardium
23. Regional ischemic ventricular dysfunction in myocardium supplied by a narrowed coronary artery with increasing halothane concentration in the dog
24. Determinants of prognosis in survivors of myocardial infarction
25. Propranolol decreases sympathetic nervous activity reflected by plasma catecholamines during evolution of myocardial infarction in man
26. Clinical investigation of techniques to protect ischemic myocardium and minimize infarct size. Final Report
27. Effect of propranolol on regional myocardial blood flow in acute ischemia
28. Effect of ischemia and antianginal drugs on the distribution of radioactive microspheres in the canine left ventricle
29. Effects of gropranolol on regional myocardial function electrocardiograms and blood flow in conscious dogs with myocardial ischemia
30. Prolonged protective effect of propranolol on hypoxic heart muscle
31. Myocardial enzyme release from ischemic isolated perfused working rat heart
32. A possible role of noradrenaline in the development of myocardial infarction An experimental study in the isolated rat heart
33. Propranolol and experimental myocardial infarction: Substrate effects
34. The effect of propranolol on microvascular injury in acute myocardial ischemia
35. Effect of practolol on the extent of myocardial ischaemic injury after experimental coronary occlusion and its effects on ventricular function in normal and ischaemic heart
36. The effect of delay in propranolol administration on reduction of myocardial infarct size after experimental coronary artery occlusion in dogs
37. Changes in infarct size following administration of propranolol in the conscious dog
38. On the nature of protection by propranolol against myocardial necrosis after temporary coronary occlusion in dogs
39. Statistical aspects of the analysis of data from retrospective studies of disease
40. Treatment of acute myocardial infarction with propranolol
41. A controlled trial of propranolol in acute myocardial infarction
42. Absence of prophylactic effect of propranolol in myocardial infarction
43. Propranolol in acute myocardial infarction
44. Clinical trial of propranolol in acute myocardial infarction
45. Trial of propranolol in acute myocardial infarction
46. The role of propranolol in the management of acute myocardial infarction
47. A trial of propranolol in myocardial infarction
48. Report on the double-blind trial with compound CIBA 39089 (Trasicor) in myocardial infarction
49. Reduction of myocardial infarct extension in man by propranolol
50. Betablocking treatment in 440 cases of acute myocardial infarction: A study with oxprenolol
51. A randomised trial of oral beta blockade during myocardial infarction: Lack of effect on enzymatic indices of myocardial necrosis
52. A prospective randomized trial of propranolol in acute myocardial infarction
53. Beta blockade in acute myocardial infarction
54. Effect of oral propranolol on the extent of acute anterior myocardial infarction
55. Practolol in acute myocardial infarction
56. Randomised trial comparing propranolol with atenolol in immediate treatment of suspected myocardial infarction
57. Randomised placebo-controlled trial comparing oxprenolol with disopyramide phosphate in immediate treatment of suspected myocardial infarction
58. An early intervention secondary prevention study with oxprenolol following myocardial infarction
59. Effect of atenolol on recovery of the electrocardiographic signs of myocardial infarction
60. Effect of beta-blockers on arrhythmias during six weeks after suspected myocardial infarction
61. Beta-adrenergic blockade and cardiac arrhymias
62. Double-blind study of the effect of cardioselective beta-blockade on chest pain in acute myocardial infarction
63. Intravenous and oral practolol in the acute stages of myocardial infarction
64. Reduction of enzyme levels by propranolol after acute myocardial infarction
65. Protective effect of propranolol in threatened myocardial infarction
66. Prophylactic selective beta blockade in acute myocardial infarction
67. Intravenous sotalol in acute myocardial infarction
68. Effects of acebutolol on myocardial infarct extension: A randomized electrocardiographic, enzymatic and angiographic study
69. Wirkung van Metropolol auf die Infarktgrosse beim akuten myokardinfarkt: Doppelblindstudie
70. Cardioprotection by beta-blockade in acute myocardial infarction
71. Reduction in infarct size, arrhythmias, chest pain, and morbidity by early intravenous beta-blockade in suspected acute myocardial infarction
72. Early intravenous beta-blockade in myocardial infarction
73. Early beta-blockade in acute myocardial infarction: Radionuclide study of infarct size and left ventricular function
74. Reduction of infarct size with the early use of timolol in acute myocardial infarction
75. Prevention of ventricular fibrillation during acute myocardial infarction by intravenous propanolol
76. Effect of IV propranolol on the extent of myocardial ischaemic injury in patients with acute anterior myocardial infarction
77. Effect of propranolol on myocardial infarct size in a randomized blinded multicenter trial
78. Metoprolol in Acute Myocardial Infarction (MIAMI). A randomised placebo controlled trial
79. Failure of pindolol to alter determinants of myocardial oxygen requirements, enzyme release or clinical course in acute myocardial infarction
80. Effect of alprenolol on mortality among patients with definite or suspected acute myocardial infarction: Preminary results
81. Limitation of myocardial infarct size in patients less than 66 years treated with alprenolol
82. Early intervention in myocardial ischaemia
83. Effect of very early intervention with metoprolol on myocardial infarct size
84. Very early intervention with metoprolol in suspected acute myocardial infarction
85. Effect on mortality of metoprolol in acute myocardial infarction: A double-blind randomised trial
86. The Göteborg metoprolol trial: Effects of mortality and morbidity in acute myocardial infarction
87. Limitation of infaret size in acute myocardial infarction with metoprolol
88. The Göteborg Metoprolol trial in acute myocardial infarction
89. Effect on long-term survival in a double-blind study with metoprolol in suspected acute myocardial infarction
90. A double-blind trial of metoprolol in acute myocardial infarction Effects on ventricular tachycardia
91. Effects of beta-adrenergic receptor blocker in myocardial infarction treated for one year from onset
92. Reduction of sudden deaths after myocardial infarction by treatment with alprenolol
93. Reduction of sudden deaths after myocardial infarction
94. Supplementary report Reduction in mortality after myocardial infarction with long-term beta-adrenoreceptor blockade
95. Multicentre post-infarction trial of propranolol in 49 hospitals in the United Kingdom, Italy and Yugoslavia
96. Effect of metoprolol after acute myocardial infarction
97. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction
98. Influence of heart size on mortality and reinfarction in patients treated with timolol after myocardial infarction
99. A multicenter study on timolol in secondary prevention after myocardial infarction
100. A long-term prevention study with oxprenolol in coronary heart disease
101. One year's treatment with propranolol after myocardial infarction: Preliminary report of Norwegian Multicentre Trial
102. A randomized trial of propranolol in patients with acute myocardial infarction I Mortality results
103. A randomized trial of propranolol in patients with acute myocardial infarction II Morbidity results
104. Controlled trial of sotalol for one year after myocardial infarction
105. Effect of treatment with 2×100 mg metoprolol on mortality in a single-center study with low placebo-mortality rate after infarction
106. A secondary prevention study with slow-release oxprenolol after myocardial infarction Morbidity and mortality
107. Influence on ventricular arrhythmias by chronic post-infarction treatment with metoprolol
108. Metoprolol after acute myocardial infarction: Evaluation of beneficial mechanism and influence on sympathoadrenal function
109. Variability of electrocardiographic and enzyme evolution of myocardial infarction in man
110. Initiation of ventricular fibrillation outside hospital in patients with acute ischaemic heart disease
111. Heart rate and ectopic prematurity in relation to sustanined ventricular arrhythmias
112. Ventricular arrhythmias in the first 12 hours of acute myocardial infarction: Natural history study
113. Plasma propranolol concentration in patients with angina and acute myocardial infarction
114. Beta-adrenergic blockade in acute myocardial infarction
115. Ischemic pain relief in patients with acute myocardial infarction by intravenous atenolol
116. Solid angle theory and the electrocardiogram Physiologic and quantitative interpretations
117. The relationship between enzymatic and histologic estimates of the extent of myocardial infarction in conscious dogs with permanent coronary occlusion
118. Early intravenous atenolol treatment in suspected acute myocardial infarction
119. Propranolol-induced reduction of signs of ischemic injury during acute myocardial infarction
120. Electrocardiographic surface mapping of the heart following myocardial infarction and the influence of beta-blockade
121. Natural history and evaluation of Q waves during myocardial infarction
122. Acute myocardial infarction: Evaluation of ST segment mapping
123. Failure of ST segment evaluation to predict severity of myocardial infarction
124. Reduction of ventricular arrhythmias by early intravenous atenolol in suspected acute myocardial infarction
125. Metoprolol and atropine in acute myocardial infarction
126. Propranolol during the evolution and subsequent 10 days of myocardial infarction in man: Hemodynamic, initial cardiac energetic and neuro-humoral responses
127. The treatment of acute myocardial infarction with beta receptor blockers: 2. Hemodynamic effects of propranolol with and without combination with nitroglycerine
128. Long-term and short-term beta-blockade after myocardial infarction
129. A comparative study of cardioselective beta-blockade and diazepam in patients with acute myocardial infarction and tachycardia
130. Propranolol treatment for myocardial infarction patients with the hyperdynamic syndrome
131. Prospective controlled trial of long-term propranolol on acute cononary events in patients with unstable coronary artery disease
132. Statistical aspects of cancer trials
133. Report of Medical Research Council Working Party on Mild to Moderate Hypertension Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension
134. The clinical importance of cardio-selectivity and lipophilicity in betablockers
135. Should every survivor of a heart attack be given a betablocker?
136. Effect of timolol on late ventricular arrhythmias after acute myocardial infarction, in Symposium on acute and long-term management of myocardial ischaemia
137. Effect of propranolol on long-term survival in patients resuscitated from out of hospital ventricular fibrillation
138. Improvement of electrocardiogram by chronic beta-adrenoceptor blockade during healing phase of clinical and experimental myocardial infarction
139. Adaptation of the heart and sympathetic system to prolonged adrenoreceptor blockade
140. Anti-platelet activity of beta-adrenergic antagonists: Inhibition of thromboxane synthesis and platelet aggregation in platelets receiving long-term propranol treatment
141. Aspirin after myocardial infarction
142. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: 1. Introduction and design
143. Influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project
144. Prevention of sudden death by propanolol in post-infarction patients with advanced grades of ventricular extra systole